The remarkable scientific advancements in recent history are due, in part, to thoughtful public policies that promote innovation and discovery. These policies support the tireless efforts of more than 140,000 biopharmaceutical researchers willing to confront seemingly impossible goals. Yet, for many patients with complex, rare or life-threatening diseases, even a single treatment option remains elusive.
Tuesday, July 17, in partnership with The Atlantic, PhRMA will bring together a diverse group of thought leaders to examine the policies that have fostered the new era of medicine and discuss how we continue to support the next generation of lifesaving therapies to benefit patients.
The event, The State of Care: Innovation and Access, will include an interview with Eli Lilly and Company CEO David Ricks on the industry’s role in advancing patient care. Also included will be a discussion with organ donor advocate Roxanne Watson, featured as part of PhRMA’s GOBOLDLY campaign, on how she benefited from innovative anti-rejection medicines after a heart transplant. Roxanne will be joined by Sharon Terry, president and CEO of the Genetic Alliance in a conversation that will be moderated by Deloitte Consulting’s managing director, Margaret Anderson.
The event will also feature a keynote interview with the Director of the U.S. Patent and Trademark Office Andrei Iancu and a panel of experts discussing the policy environment needed to support continued investment in biopharmaceutical research.
While we have made significant strides, we cannot take the rapid pace of innovation for granted. From strong intellectual property protections to regulations that support innovative payment models, a wide range of policies play a critical role in ensuring that every patient has an opportunity to triumph over their disease.
Join us online on Tuesday, July 17, from 8:15 a.m. to 10:00 a.m. EST to hear from this distinguished group of experts.
Andrew Powaleny
Andrew Powaleny is the Deputy Vice President of Public Affairs at PhRMA, where he leads communications on scientific, regulatory and intellectual property issues, highlighting the biopharmaceutical industry’s efforts in developing innovative medicines and vaccines while promoting an environment that encourages necessary risk-taking. For five years starting in 2019, he launched and led PhRMA’s grassroots initiative, Voters for Cures, bringing patients and caregivers together to advocate for access to medicine and biopharmaceutical innovation. He also co-founded and co-chaired PRIDE Umbrella, a resource group for LGBTQ+ individuals. Prior to joining PhRMA in 2015, Andrew worked as a communications consultant in Washington, D.C., and as Deputy Press Secretary for the U.S. House Committee on Energy and Commerce under Chairman Fred Upton. He holds a degree in public policy and government from Eastern Connecticut State University, with a minor in music. Outside of work, Andrew enjoys exercise, musical theater and mentoring college students through The Fund for American Studies alumni association.
Andrew Powaleny
Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change
Three things to know about the United Nations’ new HIV/AIDS report
Case study: How seniors could face access disruptions because of the IRA’s price setting provisions
ICYMI: Misaligned policies undermine patient access
3 Takeaways from POLITICO’s Health Care Summit
New analysis of patient access restrictions in the United Kingdom
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation
States can support access to medicine as COVID-19 Public Health Emergency ends
Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines
In their own words: Insured Americans support policy reforms that address access and affordability concerns
CMS coverage decision restricts access to treatments for Alzheimer’s disease
Report finds PBMs are increasingly restricting patient access to medicines
Getting the 340B program back on track in 2021
Growth in innovative, value-based contracts holds promise for the health system and for patients
Innovative contracts drive access for patients and value for the system
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
Addressing barriers that inhibit value-based contracts
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
ICYMI: Fighting for a cure to ALS
Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important
Setting the record straight on international reference pricing
"If Washington isn’t careful, we might leave innovation behind"
Giving patients a voice: PhRMA launches Voters for Cures to support the next generation of treatments and cures
Fact Check: How the Part B International Pricing Index model threatens patient access
New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid
PhRMA comments to administration on Medicare Part D proposed rule
ICYMI: New study reinforces dangers of proposed IPI model
New report shows nearly 300 cell and gene therapies in development
Groups sound the alarm on administration’s new Part B proposal
4 things you need to know about the administration’s latest Part B proposal
PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation
New report shows more than 300 skin disease medicines in development
How much do you know about Medicare Part B?
ICER’s budget impact threshold: Sounding a false alarm on affordability and access
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
Guest post: Excellent care for LGBTQ patients requires cultural humility and specific medical knowledge
Aspen Spotlight Health: Discussing the forefront of innovation
New analysis shows that more medicines worldwide are available to U.S. patients
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B
Event tomorrow: Improving patient access to lifesaving medicines
Event tomorrow: Making the biopharmaceutical supply chain work for patients
PPA celebrates 13 years of helping patients access their medicines
Copay coupons can help ease patients’ out-of-pocket costs
PhRMA launches new consumer-facing Let’s Talk About Cost website
ICYMI: Report highlights increasing prevalence for Alzheimer’s disease
Video: What is a results-based contract?
New report and event examine the new era of vaccines
A new era in cancer
How much are hospitals marking up the price of medicines? The answer may surprise you.
2017 Research & Hope Awards honor innovators in mental health
Working to harness the power of the body’s own immune system
Going boldly together: New advancements and new anniversaries
Examining the brain in The New Era of Medicine
Modernizing FDA regulations to advance a value-driven health care system
Foreign government price setting by any name harms innovation and access to medicines
Fighting multiple sclerosis: New Together ad illuminates the journey of patient & scientist
ICYMI: Avalere and FasterCures develop new value framework from patient perspective
Compulsory licensing: A misused and abused international trade law
A New World of Medicine: New GOBOLDLY ads showcase groundbreaking scientific advancements
Government-imposed price controls threaten innovation and access
ICYMI: The New Era of Medicine initiative spotlights genomics in NYC
A new era in genomics
Mental health in the New Era of Medicine
This is not a special effect: New video shows the destruction of a rogue cell
Exploring the new era of medicine
Biopharmaceutical industry’s success reducing disparities for African Americans
Medicare Monday: What is IPAB, and why is it bad for patients?
PhRMA CEO talks White House meeting, innovation & jobs with POLITICO’s Pulse Check
This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system
VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney’s Maggie Lake
The Value Collaborative: Advancing private market solutions to achieve better health, lower costs
VIDEO: PhRMA CEO joins CNBC’s Squawk on the Street to discuss industry campaign #GOBOLDLY
Event next week: Supporting the next generation of lifesaving medicines
Access
GoBoldly
Event next week: Supporting the next generation of lifesaving medicines
Event next week: Supporting the next generation of lifesaving medicines